AstraZeneca COVID shot less effective against S.African variant: study - (Financial Post via NewsPoints Desk)

  • AstraZeneca said, based on early data from a trial, its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, reported Financial Post.

  • "In this small Phase I/II trial, early data has shown limited efficacy against mild disease primarily due to the B.1.351 South African variant," said an AstraZeneca spokesman.

  • He added that "we have not been able to properly ascertain its effect against severe disease and hospitalisation given that subjects were predominantly young healthy adults."

To read more NewsPoints articles, click here.